Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian, S. L. et al. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell 41, 1551–1566 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dagher, O. K. & Posey, A. D. Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994–2007 (2023).

Article  CAS  PubMed  Google Scholar 

Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450–465 (2023).

Article  CAS  PubMed  Google Scholar 

Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2024).

Article  PubMed  Google Scholar 

Singh, N. & Maus, M. V. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity 56, 2296–2310 (2023).

Article  CAS  PubMed  Google Scholar 

Nong, C., Guan, P., Li, L., Zhang, H. & Hu, H. Tumor immunotherapy: mechanisms and clinical applications. Med. Comm. Oncol. https://doi.org/10.1002/mog2.8 (2022).

Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).

Article  Google Scholar 

Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reina-Campos, M. et al. Metabolic programs of T cell tissue residency empower tumour immunity. Nature 621, 179–187 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barry, M. & Bleackley, R. C. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2, 401–409 (2002).

Article  CAS  PubMed  Google Scholar 

Golstein, P. & Griffiths, G. M. An early history of T cell-mediated cytotoxicity. Nat. Rev. Immunol. 18, 527–535 (2018).

Article  CAS  PubMed  Google Scholar 

Wang, W. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270–274 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liao, P. et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365–378.e366 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell, H. N., Stockwell, B. R. & Zou, W. Ironing out the role of ferroptosis in immunity. Immunity 57, 941–956 (2024).

Article  CAS  PubMed  Google Scholar 

Mao, C. et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586–590 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bersuker, K. et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688–692 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).

Article  CAS  PubMed  Google Scholar 

Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stockwell, B. R. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401–2421 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia, Y. et al. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell 175, 1059–1073.e1021 (2018).

Article  CAS  PubMed  Google Scholar 

Kim, S. et al. Blocking myristoylation of Src Inhibits its kinase activity and suppresses prostate cancer progression. Cancer Res. 77, 6950–6962 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lao, Y. et al. Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma. J. Hepatol. https://doi.org/10.1016/j.jhep.2024.05.034 (2024).

Chen, B., Sun, Y., Niu, J., Jarugumilli, G. K. & Wu, X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Cell Chem. Biol. 25, 817–831 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, S. et al. Palmitoylation-dependent activation of MC1R prevents melanomagenesis. Nature 549, 399–403 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ko, P. J. & Dixon, S. J. Protein palmitoylation and cancer. EMBO Rep. 19, e46666. (2018).

Article  PubMed  PubMed Central  Google Scholar 

Qu, M., Zhou, X., Wang, X. & Li, H. Lipid-induced S-palmitoylation as a vital regulator of cell signaling and disease development. Int. J. Biol. Sci. 17, 4223–4237 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin, J., Zhi, X., Wang, X. & Meng, D. Protein palmitoylation and its pathophysiological relevance. J. Cell. Physiol. 236, 3220–3233 (2021).

Article  CAS  PubMed  Google Scholar 

Jiang, Y. et al. STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice. Sci. Signal. 16, eadd2282 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mukai, K. et al. Activation of STING requires palmitoylation at the Golgi. Nat. Commun. 7, 11932 (2016).

Article  CAS